Logo

Neurocrine Presents New Data Analyses of Ongentys (opicapone) for Parkinson Disease at ANA 2020 Virtual Meeting

Share this
Neurocrine Presents New Data Analyses of Ongentys (opicapone) for Parkinson Disease at ANA 2020 Virtual Meeting

Neurocrine Presents New Data Analyses of Ongentys (opicapone) for Parkinson Disease at ANA 2020 Virtual Meeting

Shots:

  • In a post-hoc- sub-group analysis of the P-III BIPARK-1 study demonstrated greater reductions in overnight "off" time and time to morning "on" time compared to entacapone in patients with PD with motor fluctuations
  • The new P-III post-hoc sub-group analysis demonstrated that long-term treatment with Ongentys when used as an add-on therapy reduced "On" time with troublesome dyskinesia and increased good "On" time without troublesome dyskinesia in patients with PD with motor fluctuations
  • Long term use of therapy leads to a reduction in the patient's average daily levodopa dosage requirement. Ongentys (qd- PO) is a selective and reversible COMT inhibitor and has received the US FDA’s approval as an add-on treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes

     ­ Ref: PRN | Image: Neurocrine


Click here to­ read the full press release 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions